Cargando…

Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study

INTRODUCTION: Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, Nicole K, Denehy, Linda, Edbrooke, Lara, Prado, Carla M, Ball, David, Siva, Shankar, Abbott, Gavin, Ugalde, Anna, Fraser, Steve F, Everitt, Sarah, Hardcastle, Nicholas, Wirth, Andrew, Daly, Robin M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477324/
https://www.ncbi.nlm.nih.gov/pubmed/34580100
http://dx.doi.org/10.1136/bmjopen-2021-051665
_version_ 1784575819179360256
author Kiss, Nicole K
Denehy, Linda
Edbrooke, Lara
Prado, Carla M
Ball, David
Siva, Shankar
Abbott, Gavin
Ugalde, Anna
Fraser, Steve F
Everitt, Sarah
Hardcastle, Nicholas
Wirth, Andrew
Daly, Robin M
author_facet Kiss, Nicole K
Denehy, Linda
Edbrooke, Lara
Prado, Carla M
Ball, David
Siva, Shankar
Abbott, Gavin
Ugalde, Anna
Fraser, Steve F
Everitt, Sarah
Hardcastle, Nicholas
Wirth, Andrew
Daly, Robin M
author_sort Kiss, Nicole K
collection PubMed
description INTRODUCTION: Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding of the magnitude, determinants and clinical significance of these muscle abnormalities in the lung cancer CRT/RT population. The primary objective of this study is to identify the predictors of muscle abnormalities (low muscle mass and muscle attenuation) and their depletion over time in people with lung cancer receiving CRT/RT. Secondary objectives are to assess the magnitude of change in these parameters and their association with health-related quality of life, treatment completion, toxicities and survival. METHODS AND ANALYSIS: Patients diagnosed with lung cancer and planned for treatment with CRT/RT are invited to participate in this prospective observational study, with a target of 120 participants. The impact and predictors of muscle abnormalities (assessed via CT at the third lumbar vertebra) prior to and 2 months post CRT/RT on the severity of treatment toxicities, treatment completion and survival will be assessed by examining the following variables: demographic and clinical factors, weight loss, malnutrition, muscle strength, physical performance, energy and protein intake, physical activity and sedentary time, risk of sarcopenia (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls history (SARC-F) score alone and with calf-circumference) and systemic inflammation. A sample of purposively selected participants with muscle abnormalities will be invited to take part in semistructured interviews to understand their ability to cope with treatment and explore preference for treatment strategies focused on nutrition and exercise. ETHICS AND DISSEMINATION: The PREDICT study received ethics approval from the Human Research Ethics Committee at Peter MacCallum Cancer Centre (HREC/53147/PMCC-2019) and Deakin University (2019-320). Findings will be disseminated through peer review publications and conference presentations.
format Online
Article
Text
id pubmed-8477324
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84773242021-10-08 Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study Kiss, Nicole K Denehy, Linda Edbrooke, Lara Prado, Carla M Ball, David Siva, Shankar Abbott, Gavin Ugalde, Anna Fraser, Steve F Everitt, Sarah Hardcastle, Nicholas Wirth, Andrew Daly, Robin M BMJ Open Oncology INTRODUCTION: Low muscle mass and low muscle attenuation (radiodensity), reflecting increased muscle adiposity, are prevalent muscle abnormalities in people with lung cancer receiving curative intent chemoradiation therapy (CRT) or radiation therapy (RT). Currently, there is a limited understanding of the magnitude, determinants and clinical significance of these muscle abnormalities in the lung cancer CRT/RT population. The primary objective of this study is to identify the predictors of muscle abnormalities (low muscle mass and muscle attenuation) and their depletion over time in people with lung cancer receiving CRT/RT. Secondary objectives are to assess the magnitude of change in these parameters and their association with health-related quality of life, treatment completion, toxicities and survival. METHODS AND ANALYSIS: Patients diagnosed with lung cancer and planned for treatment with CRT/RT are invited to participate in this prospective observational study, with a target of 120 participants. The impact and predictors of muscle abnormalities (assessed via CT at the third lumbar vertebra) prior to and 2 months post CRT/RT on the severity of treatment toxicities, treatment completion and survival will be assessed by examining the following variables: demographic and clinical factors, weight loss, malnutrition, muscle strength, physical performance, energy and protein intake, physical activity and sedentary time, risk of sarcopenia (Strength, Assistance in walking, Rise from a chair, Climb stairs, Falls history (SARC-F) score alone and with calf-circumference) and systemic inflammation. A sample of purposively selected participants with muscle abnormalities will be invited to take part in semistructured interviews to understand their ability to cope with treatment and explore preference for treatment strategies focused on nutrition and exercise. ETHICS AND DISSEMINATION: The PREDICT study received ethics approval from the Human Research Ethics Committee at Peter MacCallum Cancer Centre (HREC/53147/PMCC-2019) and Deakin University (2019-320). Findings will be disseminated through peer review publications and conference presentations. BMJ Publishing Group 2021-09-27 /pmc/articles/PMC8477324/ /pubmed/34580100 http://dx.doi.org/10.1136/bmjopen-2021-051665 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Kiss, Nicole K
Denehy, Linda
Edbrooke, Lara
Prado, Carla M
Ball, David
Siva, Shankar
Abbott, Gavin
Ugalde, Anna
Fraser, Steve F
Everitt, Sarah
Hardcastle, Nicholas
Wirth, Andrew
Daly, Robin M
Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title_full Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title_fullStr Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title_full_unstemmed Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title_short Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study
title_sort predicting muscle loss during lung cancer treatment (predict): protocol for a mixed methods prospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477324/
https://www.ncbi.nlm.nih.gov/pubmed/34580100
http://dx.doi.org/10.1136/bmjopen-2021-051665
work_keys_str_mv AT kissnicolek predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT denehylinda predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT edbrookelara predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT pradocarlam predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT balldavid predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT sivashankar predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT abbottgavin predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT ugaldeanna predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT fraserstevef predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT everittsarah predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT hardcastlenicholas predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT wirthandrew predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy
AT dalyrobinm predictingmusclelossduringlungcancertreatmentpredictprotocolforamixedmethodsprospectivestudy